Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies

Abstract Background Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abhinav K. Misra, Nathan L. Wong, Terrance T. Healey, Edward V. Lally, Barry S. Shea
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Interstitial lung disease Myositis-specific antibodies Polymyositis Dermatomyositis Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/4b7d055effb443ce8e13b1e660035f3c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b7d055effb443ce8e13b1e660035f3c
record_format	dspace
spelling	oai:doaj.org-article:4b7d055effb443ce8e13b1e660035f3c2021-11-21T12:39:27ZInterstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies10.1186/s12890-021-01737-71471-2466https://doaj.org/article/4b7d055effb443ce8e13b1e660035f3c2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12890-021-01737-7https://doaj.org/toc/1471-2466Abstract Background Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs. Methods We identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM/DM-associated ILD and those with ILD but no muscle or skin disease. Results A total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (p < 0.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival. Conclusions In this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM/DM.Abhinav K. MisraNathan L. WongTerrance T. HealeyEdward V. LallyBarry S. SheaBMCarticleInterstitial lung diseaseMyositis-specific antibodiesPolymyositisDermatomyositisDiseases of the respiratory systemRC705-779ENBMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Interstitial lung disease Myositis-specific antibodies Polymyositis Dermatomyositis Diseases of the respiratory system RC705-779
spellingShingle	Interstitial lung disease Myositis-specific antibodies Polymyositis Dermatomyositis Diseases of the respiratory system RC705-779 Abhinav K. Misra Nathan L. Wong Terrance T. Healey Edward V. Lally Barry S. Shea Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
description	Abstract Background Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs. Methods We identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM/DM-associated ILD and those with ILD but no muscle or skin disease. Results A total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (p < 0.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival. Conclusions In this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM/DM.
format	article
author	Abhinav K. Misra Nathan L. Wong Terrance T. Healey Edward V. Lally Barry S. Shea
author_facet	Abhinav K. Misra Nathan L. Wong Terrance T. Healey Edward V. Lally Barry S. Shea
author_sort	Abhinav K. Misra
title	Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_short	Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_full	Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_fullStr	Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_full_unstemmed	Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
title_sort	interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
publisher	BMC
publishDate	2021
url	https://doaj.org/article/4b7d055effb443ce8e13b1e660035f3c
work_keys_str_mv	AT abhinavkmisra interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies AT nathanlwong interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies AT terrancethealey interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies AT edwardvlally interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies AT barrysshea interstitiallungdiseaseisadominantfeatureinpatientswithcirculatingmyositisspecificantibodies
_version_	1718418880337018880

Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies

Ejemplares similares